Catamaran Bio
Edit info- Founded: 2020
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: RD
- Therapy area: Breast cancer, gastric cancer
- Drug types: ONC
- Lead product: CAT-179
- Funding: $42M A Nov 2020
catamaranbio.com linkedin.com job board
Business:
CAR-Natural Killer Cell Therapies
Drug notes:
CAT-248 RD renal cell carcinoma; undisclosed RD solid tumors
About:
Catamaran Bio is developing off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapies to address a broad range of cancers. NK cells are critical components of the immune system that possess natural cancer-fighting properties. Catamaran is using synthetic biology and non-viral cell engineering to create novel CAR-NK cells that are capable of treating solid tumors by combining new functional attributes with their inherent cancer-killing properties. To achieve this, Catamaran developed TAILWIND®, their proprietary suite of technologies that CAR-NK cell therapy development and manufacturing for multiple cancer types. Catamaran’s lead candidate, CAT-248, has been engineered with four functional modifications and will be tested in clinical studies for renal cell carcinoma.
Jobs:
News:
Bio-Techne launches multiplex spatial genomics assay - The Science Board
googlenews
Jul 27, 2021
Science/business updates
external-link
Cancer-fighting firm based on U of M research raises $42 million
crunchbase
Nov 24, 2020
Funding-related
external-link
Genentech alum Jane Grogan goes startup hopping from ArsenalBio to Graphite Bio; Scott Holmes to handle CFO duties at Catamaran Bio, teaming up again with ex-Disarm CEO - Endpoints News
googlenews
Apr 30, 2021
New hires
external-link
Catamaran Bio sends out life raft in tough financing climate, ending day-to-day operations
crunchbase
Jan 30, 2024
Funding-related
external-link
Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors
crunchbase
Nov 24, 2020
Funding-related
external-link
Catamaran Bio Announces Appointment of Michael DeRidder, PhD, as Senior Vice President, Corporate Strategy and New Product Planning
crunchbase
Feb 28, 2022
New hires
external-link
Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors - Business Wire
googlenews
Nov 23, 2020
Funding-related
external-link
Catamaran Bio, OmniaBio Partner To Advance Allogeneic CAR-NK Cell Therapies - Contract Pharma
googlenews
Mar 14, 2023
Science/business updates
external-link
Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies
crunchbase
Mar 14, 2022
Science/business updates
external-link
Catamaran Bio sends out life raft in tough financing climate, ending day-to-day operations - Fierce Biotech
googlenews
Jan 30, 2024
Funding-related
external-link
Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing
crunchbase
Aug 2, 2021
New hires
external-link
Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer - Business Wire
googlenews
Apr 26, 2021
New hires
external-link
Catamaran Bio sets sail with $42M to create off-the-shelf CAR-NK treatments
crunchbase
Nov 23, 2020
Funding-related
external-link
Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer - Business Wire
googlenews
Feb 4, 2021
New hires
external-link
CAR NK biotech Catamaran Bio to wind down, will seek partners for cell therapies
crunchbase
Jan 30, 2024
Science/business updates
external-link
Catamaran Bio sets sail with $42M to create off-the-shelf CAR-NK treatments - Fierce Biotech
googlenews
Nov 23, 2020
Funding-related
external-link
The Petri Dish: 2seventy bio's breakup; Catamaran Bio winds down; Third Rock expands team - Boston Business Journal
crunchbase
Feb 1, 2024
New hires
external-link
MaxCyte, Catamaran Bio Sign Strategic Platform License
crunchbase
Jan 4, 2023
Science/business updates
external-link
Bio-Techne, Progen launch Simple Plex AAV2 immunoassay - The Science Board
googlenews
Jul 28, 2021
Science/business updates
external-link
Shih, fresh from selling Disarm to Lilly, takes up CEO post at CAR-NK specialist Catamaran
crunchbase
Feb 4, 2021
New hires
external-link
Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer - Business Wire
googlenews
Apr 27, 2022
New hires
external-link
VCs investing in cell engineering for drug discovery - VatorNews
googlenews
Jul 30, 2024
Funding-related
external-link
Catamaran Bio Announces Appointment of Tara Place as Vice President, Human Resources and Organizational Effectiveness
crunchbase
Nov 15, 2021
New hires
external-link
Shih, fresh from selling Disarm to Lilly, takes up CEO post at CAR-NK specialist Catamaran - Fierce Biotech
googlenews
Feb 4, 2021
New hires
external-link
Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies
crunchbase
Mar 14, 2023
Science/business updates
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com